Results 191 to 200 of about 1,216,747 (291)

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

Arthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani, Tatsuma Ban, Yohei Kirino, Go R. Sato, Soichiro Adachi, Yuki Iizuka, Kayo Harita, Ayaka Maeda, Osamu Ohara, Hideaki Nakajima, Tomohiko Tamura   +10 more
wiley   +1 more source

Dual Effects of β‐TrCP2 Deletion in Bone Homeostasis: Suppression of Osteoclastogenesis and Enhancement of Osteoblast Activity

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to elucidate the role of beta‐transducin repeat‐containing protein 2 (β‐TrCP2) in bone homeostasis for its potential as a therapeutic target for osteoporosis. Methods The role of β‐TrCP2 in bone phenotypes was investigated using systemic β‐TrCP1 knockout (KO) and β‐TrCP2KO mice, along with myeloid‐specific ...
Woo Jung Kim, Sora Han, Hye In Ka, Sun Young Lee, Jiwon Kim, Hyunjeong Joo, Sujung Soh, Gaeun Oh, Kyung Hyun Yoo, Seung Hyun Han, Yeongkag Kwon, Choogon Lee, Kyung‐Hyun Park‐Min, Se Hwan Mun, Young Yang   +14 more
wiley   +1 more source

Plasma Proteomics Identifies Molecular Signatures and Biomarkers Associated With High Structural Damage in Ankylosing Spondylitis

Arthritis &Rheumatology, EarlyView.
Objective Pathologic bone formation in ankylosing spondylitis (AS) is not fully reflected by systemic inflammation, limiting the utility of markers of inflammation for structural damage assessment. This study aimed to identify plasma protein signatures associated with structural damage severity in AS.
Tiantian Sun, Wanlin Liu, Kun Yang, Xiaohan Xu, Yu Wang, Xinning Qu, Yifan Gong, Wenya Zhang, Jie Ma, Hongxiao Liu   +9 more
wiley   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

Process Analytical Technology (PAT) for Continuous Purification of mRNA via Precipitation and Tangential Flow Filtration

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Continuous downstream processing of messenger ribonucleic acid (mRNA) therapeutics requires purification strategies that are scalable, robust, and capable of removing product‐ and process‐related impurities from in vitro transcription mixtures.
Rajan R. Bhawnani, Maria del Carme Pons Royo, Rohan Kadambi, Andrew Hatas, Steve Burcat, Tyler Arnold, Hasan Al‐Mahayni, Richard D. Braatz, Allan S. Myerson   +8 more
wiley   +1 more source

Homologous membrane wrapped ZIF‐8 nanoparticles accelerate differentiation of neural stem cell for spinal cord injury therapy

BMEMat, EarlyView.
Homologous membrane wrapped ZIF‐8 nanoparticles were proposed to improve biocompatibility and targeting ability to neural stem cells (NSCs). ZIF‐8‐SCM NPs exhibit pH responsiveness, thereby generating an intracellular Zn2+ storm to accelerate neural differentiation through calcium and MAPK signaling pathways. Moreover, they promote function recovery in
Jie Wang, Lusen Shi, Xinhui Liu, Zhong Zhuang, Zhichao Feng, Chunhui Sun, Jingang Wang, Nik Ahmad Nizam Nik Malek, Wan Hairul Anuar Kamaruddin, Shuping Wang, Hengxing Zhou, Na Ren   +11 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source